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BACKGROUND: The renin–angiotensin system (RAS) is thought to have a role in carcinogenesis, and RAS inhibition may prevent
tumour growth.
METHODS: We retrospectively investigated the impact of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor
blockers (ARBs) in 155 patients with pancreatic cancer receiving gemcitabine monotherapy. Patients were divided into three groups: the
ACEI/ARB group (27 patients receiving an ACEI or ARB for hypertension (HT)), the non-ACEI/ARB with HT group (25 patients receiving
antihypertensive drugs other than ACEIs or ARBs), and the non-HT group (103 patients receiving no antihypertensive drugs).
RESULTS: Patient characteristics were not different, except for age and HT medications. Progression-free survival (PFS) was 8.7 months in the
ACEI/ARB group, 4.5 months in the non-ACEI/ARB with HT group, and 3.6 months in the non-HT group. Overall survival (OS) was 15.1
months in the ACEI/ARB group, 8.9 months in the non-ACEI/ARB with HT group, and 9.5 months in the non-HT group. The use of ACEIs/
ARBs was a significant prognostic factor for both PFS (P¼0.032) and OS (P¼0.014) in the multivariate analysis.
CONCLUSIONS: The ACEIs/ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic
cancer. Prospective trials are needed to test this hypothesis.
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Systemic administration of gemcitabine has been the standard
chemotherapy for advanced pancreatic cancer since Burris
et al (1997) demonstrated the superiority of gemcitabine over
5-flurouracil. Combination therapies of gemcitabine with other
cytotoxic drugs (Berlin et al, 2002; Louvet et al, 2005; Herrmann
et al, 2007; Cunningham et al, 2009; Nakai et al, 2009, 2010) have
been thoroughly investigated, but only two randomised control
trials have shown significant improvements in the survival so far
(Reni et al, 2005; Conroy et al, 2010). Many molecular target drugs
have been recently investigated in clinical trials (Van Cutsem et al,
2009; Kindler et al, 2010; Philip et al, 2010). Erlotinib in
combination with gemcitabine was the only drug that showed
prolonged survival in advanced pancreatic cancer (Moore et al,
2007) but the survival benefit was modest, with only a 2-week
improvement in survival, and was accompanied by high costs and
greater toxicity than gemcitabine alone. Thus, more effective and
safe drugs are awaited.
The systemic renin–angiotensin system (RAS) is associated with
cardiovascular regulation and angiotensin I-converting enzyme
inhibitors (ACEIs) and angiotensin II type-1 receptor blockers
(ARBs) are some of the most widely used antihypertensive drugs.
Since Lever et al (1998) reported that the use of ACEI was
associated with a decreased incidence of cancer in a large cohort
study, the potential role of the local RAS in carcinogenesis has
attracted substantial attention. The local RAS reportedly promotes
angiogenesis and proliferation via vascular endothelial growth
factor (VEGF) expression or epidermal growth factor receptor
(EGFR) expression (Ager et al, 2008; Khakoo et al, 2008).
Synergistic inhibition of tumour growth in a murine pancreatic
cancer has been demonstrated with combined gemcitabine and
losartan treatment via VEGF suppression (Noguchi et al, 2009). In
addition, the inhibition of RAS is also reported to induce apoptosis
in pancreatic cancer cells (Amaya et al, 2004; Gong et al, 2010).
Thus, the use of ACEIs or ARBs may inhibit tumour growth in
patients with pancreatic cancer. In this study, we retrospectively
analysed clinical outcomes in patients with pancreatic cancer
receiving gemcitabine monotherapy to clarify the impact of ACEIs
and ARBs.
PATIENTS AND METHODS
Patients
All patients with locally advanced and metastatic pancreatic cancer
who received first-line chemotherapy with gemcitabine mono-
therapy without previous treatment, including surgical resection
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sand radiotherapy at the University of Tokyo Hospital between
April 2001 and August 2009 were retrospectively studied. The use
of hypertension (HT) medications including ACEIs or ARBs was
retrospectively retrieved from the medical records, and patients
were divided into three groups: the ACEI/ARB group (patients who
received ACEIs or ARBs for HT), the non-ACEI/ARB with HT
group (patients who received antihypertensive drugs other than
ACEIs or ARBs), and the non-HT group (patients who did not
receive antihypertensive drugs). This study was approved by The
University of Tokyo Hospital ethics committee.
Treatment and tumour response
Gemcitabine was administered at a dose of 1000mgm
 2 in a
30-min intravenous infusion on days 1, 8, and 15 in 4-week cycles.
The relative dose intensity (RDI) for gemcitabine was defined as
the ratio of the actual dose intensity to the standard dose intensity.
Tumour response was assessed via computed tomography using
the Response Evaluation Criteria in Solid Tumours version 1.0
(Therasse et al, 2000). The evaluation was repeated every two
courses, or more frequently in patients with clinically suspected
progression.
Statistical methods
Overall survival (OS) and progression-free survival (PFS) were
estimated using the Kaplan–Meier method and compared using
the log-rank test. The w
2-test or Fisher’s exact test was used to
compare categorical variables. The independent t-test, Mann–
Whitney U-test, or Kruskal–Wallis test was used to compare
continuous variables as appropriate. All reported P-values were the
result of two-sided tests, with Po0.05 considered statistically
significant.
To exclude possible confounding factors, the Cox proportional
hazards model was used to estimate hazard ratios of the use of
ACEIs/ARBs adjusted for significant prognostic factors. Prognostic
factors included age (o65 or X65 years old), gender (male or
female), performance status (PS; 0–1 or X2), distant metastasis
(yes or no), pretreatment carbohydrate antigen 19-9 level, and
treatment group (the ACEI/ARB group, the non-ACEI/ARB with
HT group, or the non-HT group). Prognostic factors with Po0.05
in the univariate analysis were included in the multivariate
analysis.
RESULTS
Patients’ characteristics
In total, 155 patients received first-line gemcitabine monotherapy
between April 2001 and August 2009 at The University of Tokyo
Hospital, with a median follow-up time of 9.5 months. In all,
52 patients received medication for HT (Table 1) and of these,
27 patients took an ACEI (n¼6) or ARB (n¼21). Other anti-
hypertensive drugs included calcium-channel blockers (n¼22)
and b-blockers (n¼3). The most commonly administered drug
was candesartan (n¼12). The doses of ACEIs and ARBs were
as follows: enalapril 5mg in three patients and 2.5mg in one
patient, lisinopril 10mg in one patient, temocapril 4mg in
one patient, candesartan 4mg in eight patients and 8mg in four
patients, losartan 25mg in four patients, olmesartan 10mg in
three patients and valsartan 40mg in two patients. Except one
patient in the ACEI/ARB group, all the patients with HT continued
to receive their antihypertensive drugs at least during their
chemotherapy. One patient in the ACEI/ARB group stopped
taking valsartan 1 month after starting chemotherapy because
of the decrease in blood pressure. Patient characteristics of the
ACEI/ARB group (n¼27), the non-ACEI/ARB with HT group
(n¼25), and the non-HT group (n¼103) are shown in Table 2.
Baseline characteristics did not differ significantly among groups,
apart from age and HT medications. The mean RDI of gemcitabine
was 67.3% in the ACEI/ARB group, 64.6% in the non-ACEI/ARB
with HT group, and 66.4% in the non-HT group (P¼0.914). At the
time of analysis, five patients in the ACEI/ARB group and two
patients each in the non-ACEI/ARB with HT and non-HT groups
continued to receive gemcitabine without disease progression, with
a median follow-up time of 7.9 months (range, 5.2–17.3 months).
Among 146 patients who showed disease progression during
Table 1 Number of patients receiving antihypertensive drugs
Drugs Number of patients
ACEI 6
Enalapril 4
Lisinopril 1
Temocapril 1
ARB 21
Candesartan 12
Losartan 4
Olmesartan 3
Valsartan 2
Calcium-channel blockers 22
Amlodipine 8
Nifedipine 6
Manidipine 4
Diltiazem 4
b-Blockers 3
Atenolol 2
Betaxolol 1
Abbreviations: ACEI¼angiotensin I-converting enzyme inhibitor; ARB¼angiotensin
II type-1 receptor blocker.
Table 2 Patient characteristics
Characteristics
ACEI/ARB
(n¼27)
Non-ACEI/ARB
with HT (n¼25)
Non-HT
(n¼103) P-value
Median age,
years (range)
71 (53–87) 73 (56–88) 63 (41–89) o0.001
Gender
(male/female)
15/12 11/14 58/45 0.538
PS 0.621
0 1 41 14 0
1 9 13 47
24 1 1 4
3 002
Location 0.355
Head 12 16 53
Body/tail 15 9 50
Stage 0.668
Locally
advanced
12 10 40
Metastatic 15 15 63
Site of metastasis, n (%)
Liver 10 (37.0%) 12 (48.0%) 46 (44.7%) 0.942
Lung 1 (3.7%) 3 (12.0%) 13 (12.6%) 0.473
Lymph node 13 (48.2%) 12 (48.0%) 50 (48.5%) 1.000
Peritoneum 3 (11.1%) 1 (4.0%) 15 (14.6%) 0.412
Median CEA,
ngml
 1 (range)
4.0 (0.8–120.2) 6.1 (2.4–2964.3) 5.7 (1–2756.9) 0.201
Median CA19-9,
Uml
 1 (range)
490 (1–145600) 421 (1–102100) 324 (1–182600) 0.788
Hypertension 27 25 0 o0.001
Abbreviations: ACEI¼angiotensin I-converting enzyme inhibitor; ARB¼angio-
tensin II type-1 receptor blocker; CA19-9¼carbohydrate antigen 19-9;
CEA¼carcinoembryonic antigen; HT¼hypertension; PS¼performance status.
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sgemcitabine treatment, second-line chemotherapy was adminis-
tered in 23.8% of the ACEI/ARB group, 52.2% of the non-ACEI/
ARB with HT group, and 33.7% of the non-HT group (P¼0.134).
Four patents (2.6%) were lost to follow after disease progression;
one patient in the ACEI/ARB group, one patient in the non-ACEI/
ARB with HT group, and two patients in the non-HT Group. The
median follow-up period of these four patients was of 7.7 months.
Impact of ACEIs/ARBs on clinical outcomes
Response rates were comparable among the three groups; 3.7% in
the ACEI/ARB group, 4.0% in the non-ACEI/ARB with HT group,
and 2.9% in the non-HT group (P¼0.485), whereas the disease
control rate was 63.0% in the ACEI/ARB group compared with
36.0% in the non-ACEI/ARB with HT group and 44.7% in the non-
HT group (P¼0.131). The median PFS (Figure 1) was 8.7 months
(95% confidence interval (CI), 2.6–11.1) in the ACEI/ARB group,
4.5 months (95% CI, 2.2–6.1) in the non-ACEI/ARB with HT
group, and 3.6 months (95% CI, 3.1–4.8) in the non-HT group
(P¼0.015 by log-rank test). The median OS (Figure 2) was 15.1
months (95% CI, 10.2–18.5) in the ACEI/ARB group, 8.9 months
(95% CI, 6.7–11.4) in the non-ACEI/ARB with HT group, and 9.5
months (95% CI, 7.8–11.2) in the non-HT group (P¼0.140 by log-
rank test). There were no significant differences between patients
taking ACEIs and ARBs. The median PFS was 10.6 months (95%
CI, 1.5–15.1) in patients taking ACEIs and 8.2 months (95% CI,
2.0–12.9) in patients taking ARBs (P¼0.756 by log-rank test). The
median OS was 13.3 months (95% CI, 3.0–24.6) in patients taking
ACEIs and 15.6 months (95% CI, 8.7–25.4) in patients taking ARBs
(P¼0.794 by log-rank test).
Although patient characteristics of the three groups were similar
among groups except for age and HT medications, we performed
Cox proportional hazard analyses to exclude the possible influence
of confounding prognostic factors. The Cox univariate and
multivariate analyses for PFS and OS are shown in Tables 3
and 4, respectively. The use of ACEIs/ARBs remained significant
as a prognostic factor for both PFS and OS, in addition to the
previously reported prognostic factors, PS and disease stage. The
hazard ratios for the ACEI/ARB group against the non-HT group
were 0.58 (P¼0.032) for PFS and 0.52 (P¼0.014) for OS. Those for
the non-ACEI/ARB group were 0.97(P¼0.890) for PFS and 1.23
(P¼0.430) for OS.
DISCUSSION
This retrospective study is the first report to clarify the clinical
impact of the use of ACEIs or ARBs in pancreatic cancer. The use
of ACEIs or ARBs was associated with longer PFS and OS in
patients with advanced pancreatic cancer receiving gemcitabine
monotherapy. These data suggest that inhibition of the RAS in
human pancreatic cancer may inhibit tumour growth and improve
survival, in accordance with previous in vitro studies and in vivo
animal studies.
ACEIs and ARBs are widely used as antihypertensive drugs, and
the reports of organ protective effects (Grandi and Maresca, 2006)
by ACEIs are increasing, including inhibition of cardiac hyper-
trophy, diabetic nephropathy, and diabetic retinopathy. With
respect to anticancer effects, Lever et al (1998) reported that the
long-term use of ACEIs reduced the incidence of cancer in a
ACEI/ARB group
Non ACEI/ARB with HT group
Non HT group
C
u
m
u
l
a
t
i
v
e
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
Time (months)
0 12 24 36
Figure 1 Kaplan–Meier curves for progression-free survival by treat-
ment groups. The median progression-free survival was 8.7 months in the
ACEI/ARB group, 4.5 months in the non-ACEI/ARB with HT group, and 3.6
months in the non-HT group.
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Figure 2 Kaplan–Meier curves for overall survival by treatment groups.
The median overall survival was 15.1 months in the ACEI/ARB group, 8.9
months in the non-ACEI/ARB with HT group, and 9.5 months in the non-
HT group.
Table 3 Univariate and multivariate analyses for progression-free survival
Univariate analysis Multivariate analysis
Factor HR (95% CI) P-value HR (95% CI) P-value
Age, years
o65 1 0.032 1 0.605
X65 0.69 (0.50–0.97) 0.90 (0.61–1.33)
Gender
Male 1 0.387
Female 0.87 (0.62–1.20)
PS
0–1 1 o0.001 1 0.026
X2 2.69 (1.64–4.21) 2.04 (1.09–3.58)
Stage
Locally advanced 1 0.002 1 0.031
Metastatic 1.70 (1.21–2.40) 1.47 (1.04–2.10)
CA19-9
Per 1000 increase 1.01 (1.00–1.01) 0.023 1.00 (0.99–1.01) 0.559
Group
Non-HT 1 1
Non-ACEI/ARB
with HT
0.79 (0.49–1.22) 0.294 0.97 (0.58–1.56) 0.890
ACEI/ARB 0.51 (0.31–0.80) 0.003 0.58 (0.34–0.95) 0.032
Abbreviations: ACEI¼angiotensin I-converting enzyme inhibitor; ARB¼angiotensin
II type-1 receptor blocker; CA19-9¼carbohydrate antigen 19-9; CI¼confidence
interval; HR¼hazard ratio; HT¼hypertension; PS¼performance status.
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sprospective cohort study, though they did not explore the
underlying mechanisms. Since then, in addition to cardiovascular
homostasis by the systemic RAS, increasing evidence indicates a
role of the local RAS in various aspects of carcinogenesis,
including angiogenesis, cell proliferation, apoptosis, and inflam-
mation (Ager et al, 2008; Khakoo et al, 2008). On the other hand, a
meta-analysis denied the reduced cancer incidence with ACEIs
(Coleman et al, 2008) and the increased risk of cancer incidence
was also reported with ARBs (Sipahi et al, 2010). Both the clinical
impact of inhibition of RAS on cancer incidence and its underlying
mechanism remains unclear.
The existence of the local RAS was first reported in the canine
pancreas in 1991 (Chappell et al, 1991) and in the human pancreas
in 1999 (Tahmasebi et al, 1999). The local pancreatic RAS has been
implicated in various physiological conditions including pancrea-
titis, fibrosis, and diabetes mellitus (Leung, 2007). The involve-
ment of the local RAS in pancreatic cancer was suggested because
of the expression of angiotensin II (Ohta et al, 2003) and the
angiotensin II type-1 receptor (Fujimoto et al, 2001) in human
pancreatic cancer. The ACEIs and ARBs inhibit pancreatic cancer
cell proliferation in vitro (Arafat et al, 2007) and also slow murine
pancreatic cancer progression in vivo via down-regulation of
VEGF expression (Noguchi et al, 2009; Fendrich et al, 2010).
Inhibition of RAS is also reported to induce apoptosis in
pancreatic cancer cells (Amaya et al, 2004; Gong et al, 2010).
Accordingly, these drugs were suggested to be potential treatments
for pancreatic cancer or for the prevention of pancreatic cancer.
However, the clinical impact of ACEIs and ARBs in pancreatic
cancer treatment has not been fully clarified. With respect to other
cancer types, a pilot study reported that ARBs had cytostatic
activity in hormone-refractory prostate cancer, as indicated by
decreased prostate-specific antigen levels (Uemura et al, 2005),
and the addition of ACEIs/ARBs to platinum-based chemotherapy
was associated with prolonged survival in patients with advanced
non-small cell lung cancer in a retrospective study (Wilop et al,
2009). ACEIs in combination with vitamin K were also reported to
suppress the recurrence of hepatocellular carcinoma in a
prospective study (Yoshiji et al, 2009).
It is possible that ACEIs and ARBs have different influences on
cancer because ACEIs block both angiotensin II type-1 and type-2
receptors, whereas ARBs block only type-1 receptor. The role of
angiotensin II type-2 receptor is less investigated than angiotensin
II type-1 receptor, which is shown to induce angiogenesis,
proliferation, and inflammation. Angiotensin II type-2 receptor
is reported to be both anti- and pro-angiogenetic (Ager et al,
2008). In this study, there were no significant differences in
survival between patients taking ACEIs and ARBs. Our study
population was too small to analyze the differences between these
two types of drugs.
The disappointing results of combination therapy with gemci-
tabine and cytotoxic drugs have led to intense investigation
of molecular target drugs for pancreatic cancer (Burris and
Rocha-Lima, 2008). Inhibition of VEGF or EGFR failed to
demonstrate significant survival prolongation except one trial
with erlotinib (Moore et al, 2007). The inhibition of RAS by ACEI
or ARB reportedly influences multiple pathways including
angiogenesis, proliferation, and apoptosis, and can be a safe and
inexpensive strategy against pancreatic cancer, but a prospective
study is warranted to evaluate antitumour effects by the inhibition
of RAS.
This study had some limitations. As this was a retrospective
study in a single institution and the sample size of the ACEI/ARB
group was small, unknown sources of bias may exist in the
findings. However, other than age and HT medications, no
significant differences were detected in patient characteristics
among groups, and the multivariate analysis revealed that ACEI/
ARB use remained a significant prognostic factor for both PFS and
OS, though we cannot fully correct the bias that patients with HT
were much older than patients without HT. Gemcitabine dose
intensity and the induction rate of second-line chemotherapy were
also similar in the three groups. The results of the non-ACEI/ARB
with HT group also excluded the possibility that patients who did
not receive antihypertensive drugs had a poorer prognosis.
However, a prospective study with a larger population is warranted
to confirm our hypothesis.
In conclusion, our retrospective analysis suggests that ACEIs or
ARBs in combination with gemcitabine may improve clinical
outcomes in patients with advanced pancreatic cancer. We have
started a phase I trial of candesartan in combination with
gemcitabine, which is currently ongoing (UMIN registration
number 000002152).
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